Bylvay

Bylvay · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 20, 2026

13 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (64)

Nov 12, 2041method-of-use (U-3186)US 11583539
Nov 12, 2041method-of-use (U-3186)US 11583539
Nov 12, 2041method-of-use (U-3186)US 11583539
Nov 12, 2041method-of-use (U-3186)US 11583539
Nov 12, 2041method-of-use (U-3186)US 12447156
Nov 12, 2041method-of-use (U-3186)US 12447156
Nov 12, 2041method-of-use (U-3186)US 12447156
Nov 12, 2041method-of-use (U-3186)US 12447156
Jun 20, 2039compositionUS 10975046
Jun 20, 2039compositionUS 10975046
Jun 20, 2039compositionUS 10975046
Jun 20, 2039compositionUS 10975046
Jun 20, 2039method-of-use (U-3186)US 11365182
Jun 20, 2039method-of-use (U-3186)US 11365182
Jun 20, 2039method-of-use (U-3186)US 11365182
Jun 20, 2039method-of-use (U-3186)US 11365182
Jun 20, 2039formulationUS 11801226
Jun 20, 2039formulationUS 11801226
Jun 20, 2039formulationUS 11801226
Jun 20, 2039formulationUS 11801226
Jun 20, 2039formulationUS 11802115
Jun 20, 2039formulationUS 11802115
Jun 20, 2039formulationUS 11802115
Jun 20, 2039formulationUS 11802115
Jun 20, 2039compositionUS 12091394
Jun 20, 2039compositionUS 12091394
Jun 20, 2039compositionUS 12091394
Jun 20, 2039compositionUS 12091394
Jun 20, 2039method-of-use (U-3186)US 12508234
Jun 20, 2039method-of-use (U-3186)US 12508234
Jun 20, 2039method-of-use (U-3186)US 12508234
Jun 20, 2039method-of-use (U-3648)US 12508234
Nov 8, 2031method-of-use (U-3648)US 10011633
Nov 8, 2031method-of-use (U-3648)US 10011633
Nov 8, 2031method-of-use (U-3648)US 10011633
Nov 8, 2031method-of-use (U-3648)US 10011633
Nov 8, 2031method-of-use (U-3648)US 10093697
Nov 8, 2031method-of-use (U-3648)US 10093697
Nov 8, 2031method-of-use (U-3648)US 10093697
Nov 8, 2031method-of-use (U-3648)US 10093697
Nov 8, 2031method-of-use (U-3648)US 10487111
Nov 8, 2031method-of-use (U-3648)US 10487111
Nov 8, 2031method-of-use (U-3648)US 10487111
Nov 8, 2031method-of-use (U-3648)US 10487111
Nov 8, 2031method-of-use (U-3649)US 10981952
Nov 8, 2031method-of-use (U-3648)US 10981952
Nov 8, 2031method-of-use (U-3649)US 10981952
Nov 8, 2031method-of-use (U-3649)US 10981952
Nov 8, 2031method-of-use (U-3186)US 11732006
Nov 8, 2031method-of-use (U-3186)US 11732006
Nov 8, 2031method-of-use (U-3186)US 11732006
Nov 8, 2031method-of-use (U-3186)US 11732006
Nov 8, 2031method-of-use (U-3648)US 12187812
Nov 8, 2031method-of-use (U-3648)US 12187812
Nov 8, 2031method-of-use (U-3648)US 12187812
Nov 8, 2031method-of-use (U-3648)US 12187812
Nov 8, 2031method-of-use (U-3648)US 12545705
Nov 8, 2031method-of-use (U-3648)US 12545705
Nov 8, 2031method-of-use (U-3648)US 12545705
Nov 8, 2031method-of-use (U-3648)US 12545705
Nov 8, 2031method-of-use (U-3648)US 9694018
Nov 8, 2031method-of-use (U-3648)US 9694018
Nov 8, 2031method-of-use (U-3648)US 9694018
Nov 8, 2031method-of-use (U-3648)US 9694018

FDA exclusivities (16)

Jun 13, 2030ODE-436Orphan Drug (7y)3.9y
Jun 13, 2030ODE-436Orphan Drug (7y)3.9y
Jun 13, 2030ODE-436Orphan Drug (7y)3.9y
Jun 13, 2030ODE-436Orphan Drug (7y)3.9y
Jul 20, 2028ODE-363Orphan Drug (7y)2.0y
Jul 20, 2028ODE-363Orphan Drug (7y)2.0y

odevixibat

targets

all catalysts(6)

News(0)

Report a data issue

comments(0)

Patent cliff

patents (64)

FDA exclusivities (16)

🐶 often sniffed alongside

Trials studying odevixibat